Fragile histidine triad gene expression in primary prostate cancer and in an in vitro model

Zongyou Guo, Sonny L. Johansson, Johng S. Rhim, Jamboor K. Vishwanatha

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

BACKGROUND. The fragile histidine triad (FHIT) is frequently deleted and altered in many human cancers. Replacement of the FHIT gene into cancer cell lines lacking FHIT expression results in loss of tumorigenicity and tumor growth. METHODS. We investigated the status and function of the FHIT gene in the etiology of prostate carcinoma, utilizing human prostate cancer tissues and cell lines and the multistep human prostate epithelial (HPE) cell tumor model. RESULTS. In primary cancers, either no FHIT protein expression or greatly reduced expression was observed in the tumor cells, while FHIT was expressed at high levels in the adjacent normal prostate epithelia. No aberrant FHIT transcripts were observed in normal HPE cells. Aberrant transcripts were observed in the immortalized and nontumorigenic HPV-18 C-1 cell line. A tumor cell line (129 Nu 5002-1) derived from chemical transformation of HPV-18 C-1 cells did not express the FHIT gene. Immunoblot analysis of FHIT protein levels confirmed the absence of FHIT expression in the 129 Nu 5002-1 tumor cell line. Among the metastatic prostate cancer cell lines, PC-3, DU-145, and S7 exhibited aberrant transcripts, but the LNCaP cell line (early passage) was normal. Upon cloning of the cDNA and determining the DNA sequence of the PCR fragments, we observed specific alterations such as deletions and insertions in the aberrant transcripts. A majority of prostate cancer cell lines expressed the normal-sized transcript in addition to the aberrant transcripts. CONCLUSIONS. Our results indicate that alterations in the FHIT gene represent an early event in prostate carcinogenesis. (C) 2000 Wiley-Liss, Inc.

Original languageEnglish (US)
Pages (from-to)101-110
Number of pages10
JournalProstate
Volume43
Issue number2
DOIs
StatePublished - May 4 2000

Fingerprint

Histidine
Prostatic Neoplasms
Gene Expression
Prostate
Cell Line
Human papillomavirus 18
Neoplasms
Tumor Cell Line
Epithelial Cells
ethyl-2-methylthio-4-methyl-5-pyrimidine carboxylate
Genes
In Vitro Techniques
Neoplasm Genes
Organism Cloning
Carcinogenesis
Epithelium
Complementary DNA
Carcinoma
Polymerase Chain Reaction
Growth

Keywords

  • FHIT
  • Gene expression
  • HPE cells
  • Primary tumors
  • Transformation

ASJC Scopus subject areas

  • Oncology
  • Urology

Cite this

Fragile histidine triad gene expression in primary prostate cancer and in an in vitro model. / Guo, Zongyou; Johansson, Sonny L.; Rhim, Johng S.; Vishwanatha, Jamboor K.

In: Prostate, Vol. 43, No. 2, 04.05.2000, p. 101-110.

Research output: Contribution to journalArticle

Guo, Zongyou ; Johansson, Sonny L. ; Rhim, Johng S. ; Vishwanatha, Jamboor K. / Fragile histidine triad gene expression in primary prostate cancer and in an in vitro model. In: Prostate. 2000 ; Vol. 43, No. 2. pp. 101-110.
@article{dff626322db54785ab3c71ae6f459875,
title = "Fragile histidine triad gene expression in primary prostate cancer and in an in vitro model",
abstract = "BACKGROUND. The fragile histidine triad (FHIT) is frequently deleted and altered in many human cancers. Replacement of the FHIT gene into cancer cell lines lacking FHIT expression results in loss of tumorigenicity and tumor growth. METHODS. We investigated the status and function of the FHIT gene in the etiology of prostate carcinoma, utilizing human prostate cancer tissues and cell lines and the multistep human prostate epithelial (HPE) cell tumor model. RESULTS. In primary cancers, either no FHIT protein expression or greatly reduced expression was observed in the tumor cells, while FHIT was expressed at high levels in the adjacent normal prostate epithelia. No aberrant FHIT transcripts were observed in normal HPE cells. Aberrant transcripts were observed in the immortalized and nontumorigenic HPV-18 C-1 cell line. A tumor cell line (129 Nu 5002-1) derived from chemical transformation of HPV-18 C-1 cells did not express the FHIT gene. Immunoblot analysis of FHIT protein levels confirmed the absence of FHIT expression in the 129 Nu 5002-1 tumor cell line. Among the metastatic prostate cancer cell lines, PC-3, DU-145, and S7 exhibited aberrant transcripts, but the LNCaP cell line (early passage) was normal. Upon cloning of the cDNA and determining the DNA sequence of the PCR fragments, we observed specific alterations such as deletions and insertions in the aberrant transcripts. A majority of prostate cancer cell lines expressed the normal-sized transcript in addition to the aberrant transcripts. CONCLUSIONS. Our results indicate that alterations in the FHIT gene represent an early event in prostate carcinogenesis. (C) 2000 Wiley-Liss, Inc.",
keywords = "FHIT, Gene expression, HPE cells, Primary tumors, Transformation",
author = "Zongyou Guo and Johansson, {Sonny L.} and Rhim, {Johng S.} and Vishwanatha, {Jamboor K.}",
year = "2000",
month = "5",
day = "4",
doi = "10.1002/(SICI)1097-0045(20000501)43:2<101::AID-PROS4>3.0.CO;2-A",
language = "English (US)",
volume = "43",
pages = "101--110",
journal = "Prostate",
issn = "0270-4137",
publisher = "Wiley-Liss Inc.",
number = "2",

}

TY - JOUR

T1 - Fragile histidine triad gene expression in primary prostate cancer and in an in vitro model

AU - Guo, Zongyou

AU - Johansson, Sonny L.

AU - Rhim, Johng S.

AU - Vishwanatha, Jamboor K.

PY - 2000/5/4

Y1 - 2000/5/4

N2 - BACKGROUND. The fragile histidine triad (FHIT) is frequently deleted and altered in many human cancers. Replacement of the FHIT gene into cancer cell lines lacking FHIT expression results in loss of tumorigenicity and tumor growth. METHODS. We investigated the status and function of the FHIT gene in the etiology of prostate carcinoma, utilizing human prostate cancer tissues and cell lines and the multistep human prostate epithelial (HPE) cell tumor model. RESULTS. In primary cancers, either no FHIT protein expression or greatly reduced expression was observed in the tumor cells, while FHIT was expressed at high levels in the adjacent normal prostate epithelia. No aberrant FHIT transcripts were observed in normal HPE cells. Aberrant transcripts were observed in the immortalized and nontumorigenic HPV-18 C-1 cell line. A tumor cell line (129 Nu 5002-1) derived from chemical transformation of HPV-18 C-1 cells did not express the FHIT gene. Immunoblot analysis of FHIT protein levels confirmed the absence of FHIT expression in the 129 Nu 5002-1 tumor cell line. Among the metastatic prostate cancer cell lines, PC-3, DU-145, and S7 exhibited aberrant transcripts, but the LNCaP cell line (early passage) was normal. Upon cloning of the cDNA and determining the DNA sequence of the PCR fragments, we observed specific alterations such as deletions and insertions in the aberrant transcripts. A majority of prostate cancer cell lines expressed the normal-sized transcript in addition to the aberrant transcripts. CONCLUSIONS. Our results indicate that alterations in the FHIT gene represent an early event in prostate carcinogenesis. (C) 2000 Wiley-Liss, Inc.

AB - BACKGROUND. The fragile histidine triad (FHIT) is frequently deleted and altered in many human cancers. Replacement of the FHIT gene into cancer cell lines lacking FHIT expression results in loss of tumorigenicity and tumor growth. METHODS. We investigated the status and function of the FHIT gene in the etiology of prostate carcinoma, utilizing human prostate cancer tissues and cell lines and the multistep human prostate epithelial (HPE) cell tumor model. RESULTS. In primary cancers, either no FHIT protein expression or greatly reduced expression was observed in the tumor cells, while FHIT was expressed at high levels in the adjacent normal prostate epithelia. No aberrant FHIT transcripts were observed in normal HPE cells. Aberrant transcripts were observed in the immortalized and nontumorigenic HPV-18 C-1 cell line. A tumor cell line (129 Nu 5002-1) derived from chemical transformation of HPV-18 C-1 cells did not express the FHIT gene. Immunoblot analysis of FHIT protein levels confirmed the absence of FHIT expression in the 129 Nu 5002-1 tumor cell line. Among the metastatic prostate cancer cell lines, PC-3, DU-145, and S7 exhibited aberrant transcripts, but the LNCaP cell line (early passage) was normal. Upon cloning of the cDNA and determining the DNA sequence of the PCR fragments, we observed specific alterations such as deletions and insertions in the aberrant transcripts. A majority of prostate cancer cell lines expressed the normal-sized transcript in addition to the aberrant transcripts. CONCLUSIONS. Our results indicate that alterations in the FHIT gene represent an early event in prostate carcinogenesis. (C) 2000 Wiley-Liss, Inc.

KW - FHIT

KW - Gene expression

KW - HPE cells

KW - Primary tumors

KW - Transformation

UR - http://www.scopus.com/inward/record.url?scp=0034001925&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034001925&partnerID=8YFLogxK

U2 - 10.1002/(SICI)1097-0045(20000501)43:2<101::AID-PROS4>3.0.CO;2-A

DO - 10.1002/(SICI)1097-0045(20000501)43:2<101::AID-PROS4>3.0.CO;2-A

M3 - Article

C2 - 10754525

AN - SCOPUS:0034001925

VL - 43

SP - 101

EP - 110

JO - Prostate

JF - Prostate

SN - 0270-4137

IS - 2

ER -